BCL2 and B-cell chronic lymphocytic leukemia: However, nowadays, the place of the combination of obinutuzumab and chlorambucil in front-line treatment of chronic lymphocytic leukemia is significantly diminished, because the results are generally inferior to those achieved with new targeted agents, the Bruton tyrosine kinase inhibitors ibrutinib, acalabrutinib, and Zanubrutinib, and the BCL2 inhibitor venetoclax, which achieve progression-free survival rates of over 80% at 2 years [31,32,33,34].